BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-95@pharmaconomics
DTSTAMP:20260707T034116Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:AKBA Phase 2 — Praliciguat (estimated date)
DESCRIPTION:Phase 2 trial results for Praliciguat in Focal Segmental Glomerulosclerosis are due ~ Jun 30\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT07268638\n\nTrack it: https://www.pharmaconomics.com/e/95
URL:https://www.pharmaconomics.com/e/95
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:AKBA catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR